Automate Your Wheel Strategy on RMD
With Tiblio's Option Bot, you can configure your own wheel strategy including RMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RMD
- Rev/Share 34.2255
- Book/Share 37.8011
- PB 6.5136
- Debt/Equity 0.1514
- CurrentRatio 3.4113
- ROIC 0.2014
- MktCap 36102499940.0
- FreeCF/Share 10.6622
- PFCF 23.0784
- PE 27.5081
- Debt/Assets 0.111
- DivYield 0.0086
- ROE 0.2518
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RMD | Morgan Stanley | -- | Overweight | -- | -- | March 19, 2025 |
| Initiation | RMD | Goldman | -- | Buy | -- | -- | Jan. 16, 2025 |
| Initiation | RMD | Piper Sandler | -- | Neutral | -- | $252 | Jan. 10, 2025 |
| Initiation | RMD | Stifel | -- | Hold | -- | $250 | Dec. 13, 2024 |
| Initiation | RMD | Robert W. Baird | -- | Outperform | -- | $280 | Sept. 24, 2024 |
| Downgrade | RMD | Wolfe Research | Peer Perform | Underperform | -- | $180 | Sept. 18, 2024 |
News
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
Read More
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Top 15 High-Growth Dividend Stocks To Consider For May 2025
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Positive
My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming VIG's -2.46% and SPY's -5.40%, aiming for a long-term 12% return. The May 2025 Top 15 stocks offer a 1.33% average dividend yield with a 21.25% 5-year dividend growth rate and are 29% undervalued.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual's home.
Read More
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.
Read More
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions.
Read More
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Read More
My Top 15 High-Growth Dividend Stocks For March 2025
Published: March 03, 2025 by: Seeking Alpha
Sentiment: Positive
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.
Read More
Here's Why ResMed (RMD) is a Strong Growth Stock
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Read More
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Jan De Witte joins GHO Capital as Operating Partner
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies.
Read More
About ResMed Inc. (RMD)
- IPO Date 1995-06-02
- Website https://www.resmed.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Michael J. Farrell BE, MBA, SM
- Employees 9980